[1] Lundh A, Barbateskovic M, Hróbjartsson A, et al. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLOS Medicine 2010;7(10):e1000354.

[2] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109–22. doi:10.1056/NEJMoa0706628 [published Online First: 5 November 2007].

[3] Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med 2016;176(12):1826–33. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2565686.

[4] Gerstein HC, McMurray J, Holman RR. Real-world studies no substitute for RCTs in establishing efficacy. The Lancet 2019;393(10168):210–11.

[5] Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. The Lancet 2014;383(9912):156–65.